AgeTech fund: focus on over-50s not millennials

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Founding partner of 1843 Capital targets AgeTech investment opportunities with $13 million fund.

Connecticut-based early stage investment firm 1843 Capital values diversity highly, and seeks investment opportunities that reflect diversity, both in terms of the companies themselves and the markets they target. When it comes to technology development, the older population often feels like an afterthought, but 1843 is particularly keen on AgeTech companies demonstrating that they are putting older people first in their thinking.

Longevity.Technology: We know that AgeTech is a vital component of the wider longevity market, and it’s a segment that’s expected to grow significantly over the coming years. With a clear interest in investment opportunities in this area, we caught up with 1843’s founding partner Tracy Killoren Chadwell to find out more.

With a long background in investment banking and growth capital, AgeTech has always been an area of interest for Chadwell since she made a personal investment in Silvernest, a roommate matchmaking service for seniors.

“While I was doing the due diligence on Silvernest I discovered that there was this market opportunity that that no one was really talking about,” she says. “Then I learned that 83% of the capital [in the US] was held by people over 50, which I thought was remarkable because a lot of the funds in the United States are focused on millennials, and no one’s really focused on this space.”

Targeting AgeTech startups

Chadwell founded 1843 two and a half years ago, raising its first fund of $13.15 million, with what she calls “an investment thesis around longevity.”

“I always like to say if it touches someone over 50, then I’m interested,” she says, “We’ve made a market map of the whole world around the aging space, and then we have targeted areas that we are really interested in – the first one was mobility.”

This focus led to investments in autonomous shuttle service May Mobility and HopSkipDrive, which targets both children and seniors with its ride-sharing platform. “We realised that the person that’s calling a ride for their child is often the same person that would call a ride for their parent, so this was a really interesting way to get into this mobility space.”

The second area that 1843 identified for investment potential was caregiving, reflected by the firm’s most recent investment in caregiver support platform Cariloop.

“Cariloop is an enterprise software and services company that sells into corporations, providing care coaches who help individuals through their journey of caregiving,” says Chadwell. “Caregivers are so exhausted, they were one of the largest groups of committing suicide during COVID, and this is giving women or anyone in the workforce who needs that extra support when more of their loved ones needs extra care.”

Multiple AgeTech investments

To date, 1843 has made nine investments from its initial fund, and is targeting a portfolio of around 12 companies.

“We have a concentrated portfolio – I do so much work for my portfolio companies that I want to make sure that that we don’t have 30,” says Chadwell. “So we’ll do somewhere between three and four more in this particular fund.”

Predominantly focusing on Series A and B rounds, 1843’s typical first check size is around $500,000, with additional capital reserved for follow-on investment.

“We decided to go in at the best risk-return level from our research, which is Series A and Series B,” says Chadwell. “We think that at that point, a company has found its product market fit, it has also found its pricing, it’s found out who its customers are and how to get more of them. Usually they have a tangible team that you can see in place and see how they work together. And, if you’re lucky, they’ve had some experience of churn and why that’s happening – so we really have a lot of metrics to look after.”

Chadwell believe that a key differentiator of 1843’s investment philosophy is its hands-on approach.

“I think if you talk to any of the portfolio CEOs, they’ll say that we’re one of the most important parts of their team,” says Chadwell. “And I think this is because we are so well networked in this space, understand it so well, and have a worldview of it… where the more generalist firms that are writing the larger checks are more just about capital.”

The future of AgeTech

“All we do all day long is research different areas of opportunity and whitespace,” says Chadwell, who has some clear ideas on areas of AgeTech that are ripe with opportunity.

“One of the issues that has not been cracked yet, and we’ve looked at a few companies in this space, is the financial responsibility and elder fraud space,” she says. “This is a huge, very costly, very important aspect of this space, and you don’t see a Series C company in this space yet.”

“Another area is falls,” she adds. “When I talk to senior living facilities, the first issue they said was transportation, and then they said falls, because it’s so expensive for them. And they’re willing to pay to prevent it. So we’re still watching that space very closely and think probably, as vaccinations go through in this country, we’ll start to see more uptake on the revenue side for those companies.”

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Michael Antonov: longevity is all about tackling true unknowns

The Co-founder of Formic Ventures is using logic and innovation to drive the longevity sector forward. Michael Antonov is a serial entrepreneur and philanthropist who...

Shooting for the moon means going down the rabbit hole

Scientific co-operation, research collaboration and alternative financial incentives – Moon Rabbit is a crypto-conglomerate on a longevity mission. Moon Rabbit is on a mission to...